Tatsuya Yamagishi

This inventor holds 19 USPTO granted patents, plus 4 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Raqualia Pharma Inc., Pfizer Corporation, Pfizer Japan, Inc.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatsuya Yamagishi. Retrieved from https://idiyas.com/inventor/tatsuya-yamagishi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19

% Patents Active = 52.6

CIPO Patents = 4

EPO Patents = 9 (Patent Applications = 6)

Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 138(Granted Patents)

Location History:

Aichi-ken, JP (2006 - 2011)
Chita-gun, JP (2002 - 2012)
Aichi, JP (2005 - 2023)

Company Filing History:

Warner-Lambert Company

patents

6. 1 out of 28

Xuanzhu Pharma Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

TRPV4 Antagonists

Nav1.7 Blockers

Nav1.8 Blockers

TTX-S Blockers

Calcium Channel Blockers

Sodium Channel Blockers

Anti-Inflammatory Agents

Analgesic Agents

Heterocyclic Derivatives

Biaryloxy Derivatives

Pyrimidin Derivatives

Amide Derivatives

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673946 - Pyrimidin-4(3H)-one derivatives as TRPV4 antagonists (2026-07-07),

2. 12110287 - Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers (2024-10-08),

3. 11802120 - Fused cyclic urea derivatives as CRHR2 antagonist (2023-10-31),

4. 11154544 - Amide derivatives as Nav1.7 and Nav1.8 blockers (2021-10-26),

5. 11020381 - Biaryloxy derivatives as TTX-S blockers (2021-06-01),

6. 9944634 - Pyrazolopyridine derivatives as TTX-S blockers (2018-04-17),

7. 9701658 - Amide derivatives as TTX-S blockers (2017-07-11),

8. 9522140 - Aryl substituted carboxamide derivatives as calcium or sodium channel blockers (2016-12-20),

9. 9302991 - Arylamide derivatives as TTX-S blockers (2016-04-05),

10. 9187475 - Pyrrolopyridinone derivatives as TTX-S blockers (2015-11-17),

11. 9101616 - Aryl substituted carboxamide derivatives as calcium or sodium channel blockers (2015-08-11),

12. 9051296 - Aryl carboxamide derivatives as TTX-S blockers (2015-06-09),

13. 8252790 - [object Object] (2012-08-28),

14. 8084476 - Substituted methyl aryl or heteroaryl amide compounds (2011-12-27),

15. 7534914 - Substituted methyl aryl or heteroaryl amide compounds (2009-05-19),

Title: Tatsuya Yamagishi: A Trailblazer in Pharmaceutical Innovations

Introduction

Tatsuya Yamagishi, an accomplished inventor based in Aichi, Japan, has made significant contributions to the field of pharmaceuticals through his inventive works, holding an impressive total of 18 patents. His innovations primarily focus on compounds that play crucial roles in treating various medical conditions.

Latest Patents

Among his latest contributions are two remarkable patents:

1. **Heterocyclic Derivatives as Nav1.7 and Nav1.8 Blockers**

This invention pertains to heterocyclic derivatives that exhibit blocking activities of voltage-gated sodium channels Nav1.7 and Nav1.8. These compounds are promising in the treatment and prevention of disorders linked to these channels. Furthermore, the invention includes pharmaceutical compositions featuring these compounds, aimed at aiding in the management of associated diseases.

2. **Fused Cyclic Urea Derivatives as CRHR2 Antagonist**

Yamagishi's second notable patent revolves around fused cyclic urea derivatives with antagonistic properties against CRHR1 and/or CRHR2. These compounds hold potential for treating and preventing diseases related to these receptors. Similar to his other patent, this invention entails pharmaceutical compositions that utilize these derivatives for therapeutic purposes.

Career Highlights

Tatsuya Yamagishi has worked at prominent companies including Raqualia Pharma and Pfizer, where he has honed his expertise and contributed to various innovative projects. His journey has been marked by a relentless pursuit of advancements in pharmaceutical sciences, showcasing his commitment to enhancing healthcare through his inventions.

Collaborations

Throughout his career, Yamagishi has collaborated with esteemed colleagues such as Mikio Morita and Kiyoshi Kawamura. These partnerships have facilitated the sharing of knowledge and expertise, fueling the innovative spirit that drives their collective efforts in the pharmaceutical industry.

Conclusion

Tatsuya Yamagishi stands out as an exceptional inventor whose work has significantly impacted the therapeutic landscape. His dedication to developing innovative pharmaceutical compounds emphasizes the importance of continuous research and collaboration in the quest to address complex medical challenges. The future undoubtedly holds more groundbreaking contributions from this inspiring figure in the realm of pharmaceutical innovations.

Profile summary based on public USPTO records.